Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Analysis

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a publicly traded company in the HEALTHCARE sector. It trades at $12.38, carries a market capitalization of $489.39M. This page summarizes the public market data, fundamentals, and frequently asked questions for CTNM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $12.38
• Market Cap: $489.39M
• EPS: $-1.94
• 52-Week High: $16.33
• 52-Week Low: $3.57

Market Sentiment

Contineum Therapeutics, Inc. Class A Common Stock currently has a Neutral sentiment score of -0.01.

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in San Diego, California, focused on developing innovative oral small molecule therapies to address significant unmet medical needs in neuroscience, inflammation, and immunology. The company boasts a robust pipeline driven by advanced research capabilities and a commitment to scientific excellence, positioning itself to deliver effective treatments that enhance patient outcomes. With a strategic focus on addres...

GNG Research Analysis

GNG Research scores Contineum Therapeutics, Inc. Class A Common Stock (CTNM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CTNM.

Frequently Asked Questions

Does CTNM pay dividends?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) does not currently pay a regular dividend.

What is CTNM's market cap?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market capitalization of $489.39M with a current stock price of $12.38.